VTB Capital acted as a senior co-manager on the Bank of America Corporation's $4 billion domestic bond offering. VTB Capital became the first Russian bank to participate in such a transaction.
2 min read · 25 March 2013
Eye care company Bausch & Lomb Holdings, owned by private equity firm Warburg Pincus, filed with U.S. regulators to raise up to $100 million in an initial public offering, writes Reuters. The proposed IPO could raise as much as $1.5 billion and is expected to value Bausch & Lomb at about $9 billion to $10 billion, Reuters reported earlier in March.
2 min read · 25 March 2013
Here’s the latest after the weekend including the three-way battle to buyout Dell; the weekly Asian deals update; five ways big data will change your world and a look at who’s who in New England tech and biotech.
1 min read · 25 March 2013
The Oregon Investment Council, which runs the approximately $60 billion Oregon Public Employees Retirement Fund is invested in some 37 debt-related investment vehicles including, distressed debt, mezzanine and special situations funds.
2 min read · 21 March 2013
2XU, an athletic apparel business has appointed Kevin Roberts as chief executive officer. Roberts will help develop the company With the support of 2XU's three co-founding directors Clyde Davenport, Aidan Clarke and Jamie Hunt and minority investment partner Lazard Australia Private Equity.
2 min read · 21 March 2013
Sun Capital Partners has exited its investment in Sunrise Growers-Frozsun Foods. The company is a supplier of frozen strawberry products as well as a distributor and marketer of fresh strawberries. Terms of the private transaction were not disclosed.
3 min read · 21 March 2013
Valeant Pharmaceuticals International is to acquire all of the outstanding common stock of Obagi Medical Products for $19.75 per share in cash, which represents a 28 percent premium to Obagi's closing share price on March 19, 2013, the last trading day prior to announcement. The transaction is expected to close in the first half of 2013.
4 min read · 21 March 2013
Enanta Pharmaceuticals, a research and development-focused biotechnology company has announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $14.00 per share. Enanta is backed by Advent International, AlpInvest Partners, Alpha Associates, BioVentures Investors, Global Biomedical Partners, Lancet Capital, Oxford Bioscience Partners, TVM Capital and Wheatley Partners.
3 min read · 21 March 2013
Biopharma startup Poxel has appointed Khoso Baluch to its board of directors. Baluch will serve as an independent director. He is senior vice president & president European region at UCB, the global biopharmaceutical company. Poxel is backed by Edmond de Rothschild Investment Partners, InnoBio and Omnes Capital.
3 min read · 21 March 2013
This morning First Read brings you Accel's latest fundraising; an update on PE exits in Q1; zombie start-ups looking for revival and a recipe for a spectacular public crash and burn.
1 min read · 21 March 2013
